Aptevo Therapeutics (APVO) Reports FY22, Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. DRS
4. GS
5. BAC
6. UNH
7. ORCL
8. AVAV
9. ACI
10. SPY

Go back to Aptevo Therapeutics (APVO) Reports FY22, Provides Business Update

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

March 30, 2023 7:47 AM EDT

Company Achieves Multiple Clinical and Scientific Milestones in 2022, Poised for APVO436 Phase 2 in AML 2H23, ALG.APV-527 dosing initiated 1Q23 for Solid Tumors

SEATTLE, WA / ACCESSWIRE / March 30, 2023 / Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR" and ADAPTIR-FLEX" platform technologies, today reported financial results for the year ended December 31, 2022 and business highlights.

2022 Highlights

APVO436 (Acute Myeloid Leukemia)

In December 2022 we announced that APVO436, in combination with venetoclax and azacitidine, demonstrated... More